Product Specifications Research Overview IGF-1 LR3, written in the primary literature as Long-[Arg3]-IGF-I or LR3IGF-I, is an 83 residue recombinant analogue of human insulin-like growth factor 1
Companies like Nestl Health Science, Abbott, and Herbalife are developing nutrient-dense formulations focused on protein, B12, electrolytes, and appetite support, often bundled with telehealth or pharmacy programs
When food reaches the small intestine, it triggers the release of GLP-1, leading to a feeling of fullness, and stimulates the release of insulin, which lowers blood sugar
So any spending decline for groceries could be offset by more customers picking up GLP-1 prescriptions
Most patients notice early appetite changes within the first two weeks, visible weight loss by weeks three to four, and accelerated results by months two to three